RF
NBIX icon

Rossby Financial’s Neurocrine Biosciences NBIX Stock Holding History

Rossby Financial’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.3K Buy
85
+16
+23% +$2.37K ﹤0.01% 1065
2026
Q1 		$9.15K Buy
69
+42
+156% +$5.57K ﹤0.01% 1290
2025
Q4 		$3.83K Buy
27
+10
+59% +$1.45K ﹤0.01% 1194
2025
Q3 		$2.33K Buy
+17
New +$2.3K ﹤0.01% 1118

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Rossby Financial's NBIX Position: Q2 2026 in Review

Rossby Financial increased its Neurocrine Biosciences (NBIX) stake by 23% in Q2 2026, buying an estimated $2.37K and bringing the position to 85 shares worth $14.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1065.

Rossby Financial first reported a position in NBIX in Q3 2025 and has held it in 4 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Rossby Financial held 85 shares of Neurocrine Biosciences worth $14.3K as of Q2 2026.
  • Rossby Financial bought 16 Neurocrine Biosciences shares in Q2 2026, an estimated $2.37K.
  • Neurocrine Biosciences made up ﹤0.01% of Rossby Financial's portfolio in Q2 2026, its #1065 holding.
  • Rossby Financial first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Rossby Financial's 13F filing for Q2 2026, filed 4 Aug 2026.